NSD2 Is recruited through Its PHD domain to oncogenic gene loci to drive multiple myeloma

Cancer Research

Volumn 73, Issue 20, 2013, Pages 6277-6288

  Huang, Zheng ^a   Wu, Haiping ^a   Chuai, Shannon ^a   Xu, Fiona ^a   Yan, Feng ^b   Englund, Nathan ^b   Wang, Zhaofu ^a   Zhang, Hailong ^a   Fang, Ming ^a   Wang, Youzhen ^a   Gu, Justin ^a   Zhang, Man ^a   Yang, Teddy ^a   Zhao, Kehao ^a   Yu, Yanyan ^a   Dai, Jingquan ^a   Yi, Wei ^a   Zhou, Shaolian ^a   Li, Qian ^a   Wu, Jing ^a   Liu, Jun ^b   Wu, Xu ^b,d   Chan, Homan ^c   Lu, Chris ^a   Atadja, Peter ^a   Li, En ^a   Wang, Yan ^b   Hu, Min ^a   more..

^a Novartis Institutes for Biomedical Research   (China)

^b GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA SECRETASE 2; HISTONE LYSINE METHYLTRANSFERASE; NUCLEAR SET DOMAIN 2; SHORT HAIRPIN RNA; SOMATOMEDIN BINDING PROTEIN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACE2 GENE; BONE MARROW CELL; CA2 GENE; CARCINOGENESIS; CELL ADHESION; CELL INTERACTION; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME STRUCTURE; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE INACTIVATION; GENE LOCUS; GENE TARGETING; HISTONE METHYLATION; HMG DOMAIN; IGF2BP2 GENE; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR PATHOLOGY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; ONCOGENE; PHD DOMAIN; PHD1 DOMAIN; PHD2 DOMAIN; PHD5 DOMAIN; POINT MUTATION; PRIORITY JOURNAL; PWWP DOMAIN; STROMA CELL; TRANSCRIPTION INITIATION;

ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MALE; MICE; MICE, SCID; MULTIPLE MYELOMA; PROTEIN STRUCTURE, TERTIARY; REPRESSOR PROTEINS; TRANSCRIPTIONAL ACTIVATION; TRANSLOCATION, GENETIC;

EID: 84886061802     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1000     Document Type: Article

References (50)

1. Esteller M. Molecular origins of cancer: epigenetics in cancer. N Engl J Med 2008; 358:1148-59.
2. Jones PA, Baylin SB The epigenomics of cancer. Cell 2007; 128: 683-92.
3. Rodriguez-Paredes M., Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17:330-9.
4. Best JD, Carey N. Epigenetic therapies for non-oncology indications. Drug Discov Today 2010; 15:1008-14.
5. Hess JL. MLL: a histone methyltransferase disrupted in leukemia. Trends Mol Med 2004; 10:500-7.
6. Morin RD, Johnson NA, Severson T.M., Mungall AJ, An JH, Goya R, et al Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42:181-5.
7. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24:1128-38.
8. van Haaften G., Dalgliesh GL, Davies H, Chen L., Bignell G, Greenman C, et al Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009; 41:521-3.
9. Malgeri U, Baldini L, Perfetti V., Fabris S, Vignarelli MC, Colombo G, et al Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res 2000; 60:4058-61.
10. Moreau P, Facon T, Leleu X., Morineau N, Huyghe P, Harousseau J.L., et al Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100:1579-83.
11. Bergsagel PL, Kuehl WM Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23:6333-8.
12. Zhan F, Huang Y, Colla S., Stewart JP, Hanamura L, Gupta S, et al The molecular classification of multiple myeloma. Blood 2006; 108:2020-8.
13. Chesi M, Nardini E, Lim RSC, Smith KD, Kuehl W.M., Bergsagel PL The t (4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998; 92:3025-34.
14. Plowright EE, Li ZH, Bergsagel P.L., Chesi M., Barber DL, Branch DR, et al Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 2000; 95:992-8.
15. Li ZH, Zhu YX, Plowright E.E., Bergsagel PL, Chesi M, Patterson B, et al The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood 2001; 97:2413-9.
16. Chesi M, Brents LA, Fly S.A., Bais C., Robbiani DF, Mesri E, et al Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001; 97:729-36.
17. Santra M, Zhan FH, Tian E.M., Barlogie B., Shaughnessy J. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 2003; 101:2374-6.
18. Keats JJ, Reiman T, Maxwell C.A., Taylor BJ, Larratt LM, Mant MJ, et al In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003; 101:1520-9.
19. He C, Li F, Zhang J., Wu J, Shi Y. The methyltransferase NSD3 has chromatin-binding motifs, PHD5-C5HCH, that are distinct from other NSD (nuclear receptor SET domain) family members in their histone H3 recognition. J Biol Chem 2012; 288:4692-703.
20. Murphy FV, Sweet RM, Churchill MEA. Thestructure ofachromosomal high mobility group protein-DNA complex reveals sequence-neutral mechanisms important for non-sequence-specific DNA recognition. EMBO J 1999; 18:6610-8.
21. Pasillas MP, Shah M, Kamps MP NSD1PHD domains bind methylated H3K4 and H3K9 using interactions disrupted by point mutations in human sotos syndrome. Hum Mutat 2011; 32:292-8.
22. Wang GG, Cai L, Pasillas M.P., Kamps MP NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol 2007; 9:804-12.
23. Wu H, Zeng H, Lam R., Tempel W, Amaya MF, Xu C, et al Structural and histone binding ability characterizations of human PWWP domains. PLoS One 2011; 6:e18919.
24. Marango J, Shimoyama M, Nishio H., Meyer JA, Min DJ, Sirulnik A, et al The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 2008; 111:3145-54.
25. Brito JLR, Walker B, Jenner M., Dickens NJ, Brown NJM, Ross FM, et al MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica 2009; 94: 78-86.
26. Keats JJ, Maxwell CA, Taylor B.J., Hendzel MJ, Chesi M, Bergsagel PL, et al Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood 2005; 105:4060-9.
27. Pei HD, Zhang L, Luo K.T., Qin YX, Chesi M, Fei F, et al MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 2011; 470:124-U144.
28. Lauring J, Abukhdeir AM, Konishi H, Garay J.P., Gustin JP, Wang Q, et al The multiple myeloma-associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood 2008; 111:856-64.
29. Hajdu I, Ciccia A, Lewis S.M., Elledge SJ Wolf-Hirschhorn syndrome candidate 1 is involved in the cellular response to DNA damage. Proc Natl Acad Sci U S A 2011; 108:13130-4.
30. Martinez-Garcia E., Popovic R, Min D.J., Sweet SMM, Thomas PM, Zamdborg L, et al The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 2011; 117:211-20.
31. Kuo AJ, Cheung P, Chen K., Zee BM, Kioi M, Lauring J, et al NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell 2011; 44:609-20.
32. Uchiyama H, Barut BA, Chauhan D, Cannistra S.A., Anderson KC Characterization of adhesion molecules on human myeloma cell lines. Blood 1992; 80:2306-14.
33. Kim JY, Kee HJ, Choe N.W., Kim SM, Eom GH, Baek HJ, et al Multiple myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity. Mol Cell Biol 2008; 28:2023-34.
34. Hideshima T, Bergsagel PL, Kuehl W.M., Anderson KC Advances in biology of multiple myeloma: clinical applications. Blood 2004; 104: 607-18.
35. Li Y, Trojer P, Xu C.F., Cheung P., Kuo A, Drury WJ, et al The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate. J Biol Chem 2009; 284:34283-95.
36. Yuan W, Xu M, Huang C., Liu N, Chen S, Zhu B. H3K36 methylation antagonizes PRC2-mediated H3K27 methylation. J Biol Chem 2011; 286:7983-9.
37. Yuan W, Wu T, Fu H., Dai C, Wu H, Liu N., et al Dense chromatin activates Polycomb repressive complex 2 to regulate H3 lysine 27 methylation. Science 2012; 337:971-5.
38. Zheng Y, Sweet SM, Popovic R, Martinez-Garcia E, Tipton J.D., Thomas PM, et al Total kinetic analysis reveals how combinatorial methylation patterns are established on lysines 27 and 36 of histone H3. Proc Natl Acad Sci U S A 2012; 109:13549-54.
39. Asangani IA, Ateeq B, Cao Q., Dodson L, Pandhi M, Kunju L.P., et al Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell 2013; 49:80-93.
40. Wagner EJ, Carpenter PB Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol 2012; 13:115-26.
41. Todoerti K, Ronchetti D, Agnelli L., Castellani S, Marelli S, Deliliers G.L., et al Transcription repression activity is associated with the type I isoform of the MMSET gene involved in t(4;14) in multiple myeloma. Br J Haematol 2005; 131:214-8.
42. Bender LB, Suh JY, Carroll C.R., Fong YY, Fingerman IM, Briggs SD, et al MES-4: an autosome-associated histone methyltransferase that participates in silencing the X chromosomes in the C. elegans germ line. Development 2006; 133:3907-17.
43. Nielsen AL, Jorgensen P, Lerouge T., Cervino M, Chambon P, Losson R. Nizp1, a novel multitype zinc finger protein that interacts with the NSD1 histone lysine methyltransferase through a unique C2HR motif. Mol Cell Biol 2004; 24:5184-96.
44. Li HT, Ilin S, Wang W.K., Duncan EM, Wysocka J, Allis CD, et al Molecular basis for site-specific read-out of histone H3K4me3 by the BPTF PHD finger of NURF. Nature 2006; 442:91-5.
45. Zeng L, Zhang Q, Li S., Plotnikov AN, Walsh MJ, Zhou MM Mechanism and regulation of acetylated histone binding by the tandem PHD finger of DPF3b. Nature 2010; 466:258-U138.
46. Herold JM, Ingerman LA, Gao C, Frye SV Drug discovery toward antagonists of methyl-lysine binding proteins. Curr Chem Genomics 2011; 5:51-61.
47. Kurash JK, Lei H, Shen Q., Marston WL, Granda BW, Fan H, et al Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. Mol Cell 2008; 29:392-400.
48. Li Y, Reddy MA, Miao F, Shanmugam N., Yee JK, Hawkins D, et al Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kB-dependent inflammatory genes-relevance to diabetes and inflammation. J Biol Chem 2008; 283:26771-81.
49. Huang J, Dorsey J, Chuikov S., Perez-Burgos L, Zhang XY, Jenuwein T, et al G9a and Glp methylate lysine 373 in the tumor suppressor p53 (vol 285, pg 9636, 2010). J Biol Chem 2010; 285: 18122.
50. Min DJ, Ezponda T, Kim M.K., Will CM, Martinez-Garcia E, Popovic R, et al MMSET stimulates myeloma cell growth through microRNAmediated modulation of c-MYC. Leukemia 2013; 27:686-94.